{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-07-22",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Indiana",
      "state": "PA",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "89322",
      "recalling_firm": "RemedyRepack Inc.",
      "address_1": "625 Kolter Dr Ste 4",
      "address_2": "N/A",
      "postal_code": "15701-3571",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Product was distributed to two direct accounts in MI and PA.",
      "recall_number": "D-0360-2022",
      "product_description": "Cefixime 400 mg capsule, packaged in a) 2-count bottle (NDC 70518-2749-02), b) 2-count blister pack (NDC 70518-2749-03), Rx only, MFG: Ascend Labs, LLC, Montvale, NJ 07645",
      "product_quantity": "a) 716 bottles/ 1432 capsules b) 223 blister packs/ 466 capsules",
      "reason_for_recall": "Failed Impurities/Degradation Specifications",
      "recall_initiation_date": "20211229",
      "center_classification_date": "20220105",
      "termination_date": "20220414",
      "report_date": "20220112",
      "code_info": "Lot #: a) B1429436-110821, Exp 07/2022; B1429434-110821, Exp 11/2022;  B1429435-110821, Exp 11/2022;  B1279449-072021, Exp 07/2022; B1279457-072021, Exp 07/2022; B1279442-072021,Exp 07/2022; B1057718-012621, Exp 01/2022; B1057727-012621, Exp 01/2022; b) B1358139-092121, Exp 03/2022; B1424654-110421, B1437578-111421, Exp 05/2022"
    }
  ]
}